Dr. Susan Galbraith

isn't big enough really to be well-powered to show the long-term overall survival benefit.

But the Destiny Breast O5 study, which takes patients who haven't achieved a pathologic complete response and the high-risk end of that group of patients, and looked at then consolidation treatments, if you like, within HER2 for 14 cycles in that post-neuroadjuvant setting.

And the

There we saw an improvement of 53% in the reduction in the risk of invasive disease-free recurrence.

So an improvement in invasive disease-free survival of 53%, which is really important.

And so if you look at those two studies together, what that gives you confidence is that the activity that we've seen within HER2 can translate through to this improvement in the

longer-term outcomes of vet-free survival, invasive disease-free survival, and ultimately that can translate through to improvement in overall survival.

Invasive disease-free survival is an accepted end point in the early stage setting.

as a predictor for that longer term outcome.

And I think that effect size that we saw in Destiny Breast O5 was felt to be very impressive.

And again, the safety profile in Destiny Breast O5 was also felt to be impressive.

So I think, you know, if you compare the standard of care, so we use dose-dense anthracycline and cyclophosphamide.

The alternative would be a combination of zactine and carboplatin.

And actually, there are other side effects that you get with that regimen.

The difference in choice between DDAC or the TCTHP regimen is really a regional choice.

If you go to the West Coast of the US, a higher proportion of doctors will choose the TCTHP.

The East Coast, a higher proportion choose the AC.

Actually, if you look at the Destiny Breast O5 study, about half of patients were treated with one or the other regimen.

And based on all of the data sets that are out there,

that have been reviewed, it's accepted that the efficacy is similar between those two regimens.